Introduction:  Carcinoma of prostate is one of the most common cancers and ranks as the second most common cause of cancer death in men. The most common histologic type is adenocarcinoma and prostate cancer screening consists of  measurement of PSA concentration in serum and digital rectal

examination. Positivity in one of these tests make patients candidates for further diagnostic evaluation with a transrectal ultrasonography–guided prostate biopsy.

 Aim :The study was undertaken to define the role of TRUS biopsy of prostate for the diagnosis of carcinoma of prostate and to correlate histopathological findings with serum PSA levels, abnormal DRE( digital rectal examination) and  clinical suspicion.

Materials & Methods: TRUS guided biopsy was done  using  a rectal probe (7.5 MHz ) on a E–Saote MyLab 60 ultrasound–colour Doppler system over a period of two years in 92 patients. We followed 8 core biopsy technique for specimen collection.

Results: Out of 92 patients, 45 patients were diagnosed as malignant, 43 patients were diagnosed as non–malignant and 4 patients were diagnosed as inconclusive.

Conclusion: TRUS guided  prostate biopsy remains an essential tool for the diagnosis of carcinoma of prostate and individualization of management decisions.